1 Aug 2016 12:00
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Presentation at the Canaccord Genuity 36th Annual Growth Conference, Boston
Wednesday 10th August, 2016 at 9am EDT / 2pm BST
London, UK, 1 August 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announces that its Chief Executive Officer, Carl Sterritt, will be presenting at the Canaccord Genuity 36th Annual Growth Conference in Boston on Wednesday 10th August, 2016 at 9am EDT / 2pm BST.
To register for the live webcast please visit http://wsw.com/webcast/canaccord23/stx.l. A replay will also be made available on the Company's website at http://www.shieldtherapeutics.com/.
- Ends -
For further information on the Company or if you would like to arrange a meeting with Shield Therapeutics at the conference, please contact:
Shield Therapeutics plc | +44 (0)207 186 8500 |
Carl Sterritt, Chief Executive Officer Richard Jones, Chief Financial Officer
| info@shieldtx.com |
NOMAD Liberum Capital Limited Christopher Britton/Steve Pearce
| +44 (0)20 3100 2222 |
Financial PR Advisor Consilium Strategic Communications | +44 (0)203 709 5700 shieldtherapeutics@consilium-comms.com |
Mary-Jane Elliott/Matthew Neal/Lindsey Neville/Hendrik Thys |
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Company has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA). In addition, the Company is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com.
Shield Thera (STX)